Proangiogenic signalling pathways are activated in chronic inflammation, but although antiangiogenic treatments are routinely incorporated into cancer therapy, surprisingly few clinical trials have investigated this approach in patients with chronic inflammatory diseases. However, this situation could soon change — a wide range of small-molecule inhibitors with improved specificity, and techniques to target such inhibitors to specific cell types, are currently undergoing clinical and preclinical development.
- Sander W. Tas
- Chrissta X. Maracle
- Zoltán Szekanecz